Rapid initial decline in BCR-ABL1 is associated with superior responses to second-line nilotinib in patients with chronic-phase chronic myeloid leukemia

BACKGROUND: We evaluated BCR-ABL1 kinetics in patients treated with nilotinib and analyzed whether a dynamic model of changes in BCR-ABL1 levels over time could be used to predict long-term responses. METHODS: Patients from the nilotinib registration trial (CAMN107A2101; registered at http://www.cli...

Descripción completa

Detalles Bibliográficos
Autores principales: Stein, Andrew M, Martinelli, Giovanni, Hughes, Timothy P, Müller, Martin C, Beppu, Lan, Gottardi, Enrico, Branford, Susan, Soverini, Simona, Woodman, Richard C, Hochhaus, Andreas, Kim, Dong-Wook, Saglio, Giuseppe, Radich, Jerald P
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2013
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3646679/
https://www.ncbi.nlm.nih.gov/pubmed/23547655
http://dx.doi.org/10.1186/1471-2407-13-173

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3646679/
https://www.ncbi.nlm.nih.gov/pubmed/23547655
http://dx.doi.org/10.1186/1471-2407-13-173

Ejemplares similares